PriceTargets.com logo

ZIOPHARM Oncology - ZIOP Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 12/31/1969 06:45 PM ET
+0 (0.00%)
Get New ZIOPHARM Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZIOP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZIOP

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for ZIOPHARM Oncology in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for ZIOP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in ZIOPHARM Oncology. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/27/2022Raymond JamesSet TargetMarket Perform$2.00Low
11/22/2021HC WainwrightReiterated RatingHoldHigh
11/9/2021Raymond JamesLower TargetMarket Perform$3.00 ➝ $2.00High
8/10/2021Lake Street CapitalLower TargetBuy$7.00 ➝ $3.50High
8/9/2021Raymond JamesDowngradeOutperform ➝ Market Perform$3.00High
5/10/2021HC WainwrightReiterated RatingHoldHigh
5/7/2021Raymond JamesLower TargetOutperform$5.50 ➝ $4.00High
3/18/2021Jefferies Financial GroupReiterated RatingBuy ➝ Hold$7.00 ➝ $5.00High
3/12/2021Raymond JamesSet TargetOutperform$5.50High
3/12/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$7.00 ➝ $5.00High
3/8/2021HC WainwrightReiterated RatingBuy ➝ NeutralHigh
3/1/2021HC WainwrightDowngradeBuy ➝ NeutralLow
2/26/2021Raymond JamesSet TargetOutperform$5.50High
11/20/2020Raymond JamesReiterated RatingBuy$5.50High
11/6/2020Raymond JamesSet TargetOutperform$5.50Low
9/15/2020Raymond JamesSet TargetOutperform$5.50Low
8/7/2020Raymond JamesSet TargetOutperform$5.50Low
7/10/2020Raymond JamesSet TargetOutperform$5.50Low
6/21/2020LaidlawReiterated RatingBuy$7.50High
6/21/2020Cantor FitzgeraldReiterated RatingOverweight ➝ Market Perform$6.00High
6/19/2020Jefferies Financial GroupInitiated CoverageBuy$7.00High
6/8/2020Cantor FitzgeraldReiterated RatingOverweightMedium
5/28/2020Raymond JamesSet TargetOutperform$5.50High
5/11/2020HC WainwrightReiterated RatingBuy$6.50 ➝ $5.50High
5/8/2020Raymond JamesSet TargetOutperform$5.50Low
3/3/2020Cantor FitzgeraldInitiated CoverageOverweight$6.00High
3/3/2020HC WainwrightReiterated RatingBuy$6.50Low
3/3/2020Raymond JamesLower TargetOutperform$6.50 ➝ $5.50High
1/17/2020Raymond JamesSet TargetOutperform$6.50High
12/10/2019Raymond JamesSet TargetOutperform$6.50Low
12/10/2019HC WainwrightReiterated RatingBuy$6.50High
11/25/2019Raymond JamesSet TargetOutperform$6.50High
11/8/2019Raymond JamesSet TargetOutperform$6.50High
10/29/2019Raymond JamesReiterated RatingOutperform$6.50Low
10/2/2019Raymond JamesSet TargetOutperform$6.50Low
10/2/2019HC WainwrightReiterated RatingBuy$6.50Low
8/22/2019Raymond JamesInitiated CoverageOutperform$6.50High
5/9/2019HC WainwrightReiterated RatingBuy$5.50Medium
(Data available from 4/24/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
ZIOPHARM Oncology logo
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.08
Low: $0.82
High: $1.39

52 Week Range

Now: N/A

Volume

2,127,500 shs

Average Volume

2,008,312 shs

Market Capitalization

$187.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

Frequently Asked Questions

What sell-side analysts currently cover shares of ZIOPHARM Oncology?

The following Wall Street sell-side analysts have issued stock ratings on ZIOPHARM Oncology in the last year: StockNews.com.
View the latest analyst ratings for ZIOP.

What is the current price target for ZIOPHARM Oncology?

0 Wall Street analysts have set twelve-month price targets for ZIOPHARM Oncology in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for ZIOPHARM Oncology in the next year.
View the latest price targets for ZIOP.

What is the current consensus analyst rating for ZIOPHARM Oncology?

ZIOPHARM Oncology currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ZIOP.

What other companies compete with ZIOPHARM Oncology?

Other companies that are similar to ZIOPHARM Oncology include Rigel Pharmaceuticals, Merrimack Pharmaceuticals, Regulus Therapeutics, Verastem and Emergent BioSolutions. Learn More about companies similar to ZIOPHARM Oncology.

How do I contact ZIOPHARM Oncology's investor relations team?

ZIOPHARM Oncology's physical mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company's listed phone number is (617) 259-1970 and its investor relations email address is [email protected]. The official website for ZIOPHARM Oncology is www.ziopharm.com. Learn More about contacing ZIOPHARM Oncology investor relations.